Tralokinumab DOI

Reactions Weekly, Год журнала: 2023, Номер 1980(1), С. 378 - 378

Опубликована: Окт. 27, 2023

Язык: Английский

Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options DOI
Carlo Alberto Maronese, Mario Valenti, Chiara Moltrasio

и другие.

Journal of Investigative Dermatology, Год журнала: 2024, Номер 144(11), С. 2364 - 2376

Опубликована: Июль 2, 2024

Язык: Английский

Процитировано

9

Identification of novel biomarkers associated with immune infiltration in major depression disorder and atopic dermatitis DOI
Han Jiang,

Bizhen Gong,

Z.-Q. Yan

и другие.

Archives of Dermatological Research, Год журнала: 2025, Номер 317(1)

Опубликована: Фев. 15, 2025

Язык: Английский

Процитировано

0

Chronic Hand Eczema (CHE): A Narrative Review DOI Creative Commons

G. Ghezzi,

Costanza Falcidia,

Giovanni Paolino

и другие.

Dermatology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Март 10, 2025

Chronic hand eczema (CHE) is a common and challenging skin condition, characterized by persistent dermatitis which lasts over 3 months or recurs at least twice year. This condition often multifactorial, involving genetic predispositions, environmental factors triggers, such as irritants allergens. Studies show higher incidence in women, though prevalence estimates vary across different age groups. The pathogenesis involves complex immune mechanisms, particularly Th1/Th2 cell responses. Clinically, CHE presents various forms, with symptoms redness, scaling itching that significantly impact patients' quality of life. Treatment approaches are diverse. While emollients topical corticosteroids have historically been the mainstay, new systemic therapies like JAK inhibitors biologics progressively being used for severe cases. Key molecular targets comprise interleukin (IL)-4 IL-13, JAK-STAT pathway, phosphodiesterase 4 (PDE4) chemoattractant chemokines. Managing effectively remains challenge because its chronicity variability individual responses to treatment. However, emerging therapeutic strategies will help clinicians offer more patient-centred approaches.

Язык: Английский

Процитировано

0

Efficacy and Safety of Dupilumab in the Treatment of Refractory Atopic Dermatitis in Older Adults: A Retrospective, Single-Center Study DOI

Ren Cai,

Jinwen Huang, Caifeng Chen

и другие.

Drugs & Aging, Год журнала: 2025, Номер unknown

Опубликована: Апрель 5, 2025

Язык: Английский

Процитировано

0

New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis DOI Open Access

Vittorio Tancredi,

Dario Buononato, Stefano Caccavale

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 25(1), С. 362 - 362

Опубликована: Дек. 27, 2023

Chronic hand eczema (CHE) is a common inflammatory skin condition that significantly impacts the quality of life. From work-related disabilities to social embarrassment, pain, and financial costs, burden on society substantial. Managing this presents challenges such as long-term treatment, poor patient compliance, therapy side effects, economic feasibility. As result, significant efforts have been made in field recent years. Specifically, broader understanding CHE pathogenesis has led development new drugs, both topical systemic. The aim narrative review summarize current available data pathophysiology explore resulting developments drugs for its treatment. A comprehensive search PubMed other main scientific databases was conducted using keywords related pathogenesis. most relevant pathways targeted by therapies include JAK-STAT cascade, IL-4, IL-13 axis, phosphodiesterase 4 enzyme, chemo-attractant cytokines. In near future, physicians will plethora therapeutic alternatives. Consequently, they should be well-trained not only how use these alternatives but also combine treatments address ongoing efficacy, tolerability, safety.

Язык: Английский

Процитировано

7

Paradoxical psoriasis after dupilumab treatment of prurigo nodularis treated with adalimumab DOI Creative Commons

Jennifer Astrup Sørensen,

Cæcilie Bachdal Johansen, Alexander Egeberg

и другие.

JAAD Case Reports, Год журнала: 2024, Номер 52, С. 146 - 149

Опубликована: Авг. 23, 2024

Язык: Английский

Процитировано

2

Paradoxical Psoriasis DOI
Mariam Abdelghaffar,

Sita Kottilil,

Michael J. Murphy

и другие.

Dermatologic Clinics, Год журнала: 2024, Номер 42(3), С. 471 - 480

Опубликована: Апрель 10, 2024

Язык: Английский

Процитировано

1

Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions DOI Open Access
Lichen Li, Dean J. Naisbitt, Yonghu Sun

и другие.

Clinical & Experimental Allergy, Год журнала: 2024, Номер 54(12), С. 973 - 983

Опубликована: Окт. 20, 2024

ABSTRACT Biological agents are widely used across medicine, including for immune‐mediated skin conditions such as psoriasis and atopic dermatitis. When to treat a relevant pathological process, they demonstrate impressive efficacy credible safety, helping achieve remission improved function quality of life. However, with their expanded use, awareness understanding adverse reactions biologicals have also increased. Herein, we discuss the pathomechanism biological apply these Pichler's classification system. This differentiates five distinct types, namely overstimulation (type α), hypersensitivity or immunogenicity (β), immunodeviation (γ), cross‐reactivity (δ) nonimmunologic (ε). covers most types associated use could be better understand reaction pathogenesis manage clinical features effects.

Язык: Английский

Процитировано

1

Successful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review DOI Creative Commons

Misuzu Tsunoda,

Takeya Adachi,

Yuuri Nakajima

и другие.

Journal of Allergy and Clinical Immunology Global, Год журнала: 2024, Номер 3(4), С. 100323 - 100323

Опубликована: Авг. 6, 2024

Dupilumab-induced psoriatic dermatitis and arthritis in a patient with atopic were effectively managed upadacitinib, highlighting the use of Janus kinase inhibitors as possible treatment for biologic therapy side effects.

Язык: Английский

Процитировано

0

The role of immune inflammatory response and inflammatory infiltrates in major depression disorder and atopic dermatitis: new insights from machine learning DOI Creative Commons
Han Jiang,

Bizhen Gong,

Mengxi Yao

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Окт. 18, 2023

Abstract Background Major depression disorder (MDD) and atopic dermatitis (AD) are distinct disorders involving immune inflammatory responses. This study aimed to investigate the comorbid relationship between AD MDD identify possible common mechanisms. Methods We obtained data from Gene Expression Omnibus (GEO) database. Differential expression analysis Genecard database were employed shared genes associated with diseases. These then subjected gene ontology (GO) Kyoto Encyclopedia of Genes Genomes (KEGG) pathway enrichment analyses. Hub selected based on protein-protein interactions using CytoHubba, key regulatory identified through analysis. Subsequently, we conducted infiltration correlation analyses in AD. Finally, three machine learning models predict significance genes. Results A total 17 AD_Inflammatory_MDD dataset (S100A9, PTGER2, PI3, SNCA, DAB2, PDGFA, FSTL1, CALD1, XK, UTS2, DHRS9, PARD3, NFIB,TMEM158, LIPH, RAB27B, SH3BRL2). biological processes such as regulation mesenchymal cell proliferation, glial differentiation. The neuroactive ligand-receptor interaction, IL-17 signaling, Rap1 signaling pathways significantly enriched KEGG S100A9, SH3BGRL2, TMEM158, XK hub contributing development. consistently SNCA PARD3 important biomarkers. Conclusion significant development comorbidities. Immune showed a notable increase various subtypes CD4+ T cells, suggesting potential association skin inflammation response. Across different models, emerged

Язык: Английский

Процитировано

0